Invasive giant prolactinoma with loss of therapeutic response to cabergoline: Expression of angiogenic markers

Endocrine Pathology

Volumn 20, Issue 1, 2009, Pages 35-40

  Mallea Gil, María Susana ^a   Cristina, Carolina ^b   Perez Millan, María Inés ^b   Villafañe, Ana M Rodriguez ^a   Ballarino, Carolina ^a   Stalldecker, Graciela ^c   Becu Villalobos, Damasia ^b  

^a HOSPITAL MILITAR CENTRAL   (Argentina)

^b Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^c HOSPITAL DURAND   (Argentina)

Author keywords

Dopamine agonist resistance; FGF; IGFI; Ki67; Prolactinoma; VEGF

Indexed keywords

CABERGOLINE; CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR 2; GROWTH HORMONE; KI 67 ANTIGEN; OCTREOTIDE; SOMATOMEDIN C; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ERGOLINE DERIVATIVE; PROLACTIN; TUMOR MARKER;

AGED; AMNESIA; ARTICLE; ATTENTION DISTURBANCE; BRAIN THIRD VENTRICLE; CANCER INVASION; CASE REPORT; DRUG DOSE INCREASE; FATALITY; GAIT DISORDER; GROWTH HORMONE RELEASE; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROLACTINOMA; SLEEP DISORDER; TEMPORAL LOBE; TUMOR GROWTH; TUMOR VASCULARIZATION; VISUAL IMPAIRMENT; BLOOD; DRUG RESISTANCE; GENETICS; HYPOPHYSIS TUMOR; HYPOTHYROIDISM; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; ERGOLINES; HUMANS; HYPOTHYROIDISM; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MALE; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; PROLACTIN; PROLACTINOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 66349120511     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9057-3     Document Type: Article

References (37)

1. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, et al. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol (Oxf) 58:662-670, 2003. doi:10.1046/j.1365-2265.2003.01770.x. (Pubitemid 36566810)
2. Lundin P, Pedersen F. Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16:519-528, 1992. doi:10.1097/00004728-199207000- 00004.
3. Molitch ME. Pharmacologic resistance in prolactinoma patients. Pituitary 8:43-52, 2005. doi:10.1007/s11102-005-5085-2. (Pubitemid 44680085)
4. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, et al. Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79:804-812, 1997. doi:10.1002/(SICI)1097- 0142(19970215)79:4<804::AID- CNCR18>3.0.CO;2-3. (Pubitemid 27076347)
5. Delgrange E, Crabbe J, Donckier J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm Res 49:250-253, 1998. doi:10.1159/000023180. (Pubitemid 28165744)
6. McCall D, Hunter SJ, Cooke RS, Herron B, Sheridan B, Atkinson AB. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin Endocrinol (Oxf) 66:149-150, 2007. (Pubitemid 44952509)
7. Turner HE, Nagy Z, Gatter KC, Esiri MM, Harris AL, Wass JA. Angiogenesis in pituitary adenomas-relationship to endocrine function, treatment and outcome. J Endocrinol 165:475-481, 2000. doi:10.1677/joe.0.1650475. (Pubitemid 30341096)
8. Mucha SA, Melen-Mucha G, Godlewski A, Stepien H. Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat. Virchows Arch 450:335-341, 2007. doi:10.1007/ s00428-006-0351-x. (Pubitemid 46376557)
9. Pawlikowski M, Grochal M, Kulig A, Zielinski K, Stepien H, Kunert-Radek J, et al. The effect of angiotensin II receptor antagonists on diethylstilbestrol-induced vascular changes in the rat anterior pituitary gland: a quantitative evaluation. Histol Histopathol 11:909-913, 1996. (Pubitemid 26364214)
10. Stepien H, Grochal M, Zielinski KW, Mucha S, Kunert-Radek J, Kulig A, et al. Inhibitory effects of fumagillin and its analogue TNP-470 on the function, morphology and angiogenesis of an oestrogen-induced prolactinoma in Fischer 344 rats. J Endocrinol 150:99-106, 1996. doi:10.1677/joe.0.1500099.
11. Gorczyca W, Hardy J. Microadenomas of the human pituitary and their vascularization. Neurosurgery 22:1-6, 1988. doi:10.1097/ 00006123-198801010- 198900001
12. de la Torre NG, Wass JA, Turner HE. Morphologic changes and molecular regulation of angiogenesis in pituitary adenomas. Front Horm Res 32:133-145, 2004. doi:10.1159/000079042.
13. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 18:4-25, 1997. doi:10.1210/er.18.1.4. (Pubitemid 27076453)
14. Bikfalvi A, Klein S, Pintucci G, Rifkin DB. Biological roles of fibroblast growth factor-2. Endocr Rev 18:26-45, 1997. doi:10.1210/er.18.1.26. (Pubitemid 27076454)
15. Komorowski J, Jankewicz J, Stepien H. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios 101:151-159, 2000.
16. Cristina C, Diaz-Torga G, Gongora A, Guida MC, Perez-Millan MI, Baldi A, et al. Fibroblast Growth Factor-2 in hyperplastic pituitaries of D2R knockout female mice. Am J Physiol Endocrinol Metab 293:E1341-51, 2007. doi:10.1152/ ajpendo.00260.2007.
17. Cristina C, Diaz-Torga G, Baldi A, Gongora A, Rubinstein M, Low MJ, et al. Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice. Endocrinology 146:2952-2962, 2005. doi:10.1210/en.2004-1445. (Pubitemid 41002802)
18. Kim K, Yoshida D, Teramoto A. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in pituitary adenomas. Endocr Pathol 16:115-21, 2005. doi:10.1385/ EP:16:2:115. (Pubitemid 41400352)
19. Minematsu T, Suzuki M, Sanno N, Takekoshi S, Teramoto A, Osamura RY. PTTG overexpression is correlated with angiogenesis in human pituitary adenomas. Endocr Pathol 17:143-153, 2006. doi:10.1385/EP:17:2:143. (Pubitemid 44965903)
20. Piroli G, Torres A, Grillo C, Lux-Lantos V, Aoki A, De Nicola AF. Mechanisms in progestin antagonism of pituitary tumorigenesis. J Steroid Biochem Mol Biol 64:59-67, 1998. doi:10.1016/ S0960-0760(97)00139-148
21. Brue T, Pellegrini I, Priou A, Morange I, Jaquet P. Prolactinomas and resistance to dopamine agonists. Horm Res 38:84-89, 1992.
22. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sexrelated difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82:2102-2107, 1997. doi:10.1210/jc.82.7.2102. (Pubitemid 27287568)
23. Maraschini C, Moro M, Masala A, Toja P, Alagna S, Brunani A, et al. Chronic treatment with parlodel LAR of patients with prolactin-secreting tumours. Different responsiveness of microand macroprolactinomas. Acta Endocrinol (Copenhagen) 125:494-501, 1991.
24. Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol 8:737-746, 1996. doi:10.1046/j.1365-2826.1996. 04902.x.
25. Caccavelli L, Feron F, Morange I, Rouer E, Benarous R, Dewailly D, et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 60:314-322, 1994. doi:10.1159/000126764.
26. Ferrara N, Gerber H, LeCouter J. The biology of VEGF and its receptors. Nat Med 9:669-676, 2003. doi:10.1038/nm0603-669. (Pubitemid 36749215)
27. Schechter J, Goldsmith P, Wilson C, Weiner R. Morphological evidence for the presence of arteries in human prolactinomas. J Clin Endocrinol Metab 67:713-719, 1988.
28. Jugenburg M, Kovacs K, Stefaneanu L, Scheithauer BW. Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: a quantitative morphologic study. Endocr Pathol 6:115-124, 1995. doi:10.1007/BF02739874.
29. Lloyd RV, Scheithauer BW, Kuroki T, Vidal S, Kovacs K, Stefaneanu L. Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas. Endocr Pathol 10:229-235, 1999. doi:10.1007/BF02738884.
30. McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, et al. Vascular endothelial growth factor, its receptor KDR/ Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 87:4238-4244, 2002. doi:10.1210/jc.2002-020309.
31. Arita K, Kurisu K, Tominaga A, Sugiyama K, Eguchi K, Hama S, et al. Relationship between intratumoral hemorrhage and overexpression of vascular endothelial growth factor (VEGF) in pituitary adenoma. Hiroshima J Med Sci 53:23-27, 2004.
32. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, et al. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574, 2001. doi:10.1038/87895. (Pubitemid 32448324)
33. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S. Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349-4356, 2004. doi:10.1158/1078-0432. CCR-04-0059.
34. Cristina C, García-Tornadú I, Diaz-Torga G, Rubinstein M, Low MJ, Becu-Villalobos D. The dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res 35:50-63, 2006. doi:10.1159/000094308. (Pubitemid 44024241)
35. Gaffey TA, Scheithauer BW, Lloyd RV, Burger PC, Robbins P, Fereidooni F, et al. Corticotroph carcinoma of the pituitary: a clinicopathological study. Report of four cases. J Neurosurg 96:352-360, 2002.
36. Gurlek A, Karavitaki N, Ansorge O,Wass JA.What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156:143-153, 2007. doi:10.1530/eje.1.02339. (Pubitemid 46554508)
37. Oliveira MC, Marroni CP, Pizarro CB, Pereira-Lima JF, Barbosa- Coutinho LM, Ferreira NP. Expression of p53 protein in pituitary adenomas. Braz J Med Biol Res 35:561-565, 2002.